Aurobindo Pharma has declared that the US FDA has given tentative nod for Rosuvastatin Calclum pills in strengths of 5mg, 10mg, 20mg and 40mg.

According to the company, Resuvastatin Calclum tabs, which comes under cardio vascular (CVS) therapeutic family, treats high LDL cholesterol and total cholesterol level.

For the year ended Dec 31, 2009, Resuvastatin Calclum tabs hold a market size of $ 2.9 billion in the United States.

With this, Aurobindo now has 116 ANDA approvals comprising 86 final nods and 30 tentative sanctions from USFDA.

Moreover, the company on May 06 bagged sanction for its Abbreviated New Drug Submission for Cyclobenzaprine tabs from Health Canada.

For Cyclobenzaprine, Aurobindo got nod in the strength of 10 mg.

Now, Aurobindo has 12 products sanctioned by Health Canada.

On Thursday, the shares of the company gained 2.4% to end at Rs 895.60. The total volume of shares traded was 8,220 at the BSE.